PDCD1 and non-small cell lung carcinoma: In the realm of IT and metabolomics, Nie et al. [26] sought to utilize early on-treatment plasma metabolomic profiling to identify predictors of clinical outcomes in advanced NSCLC patients undergoing anti-PD-1 treatment.